drugset / Trial / NCT00968942

Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968942

Phase 2 Completed 36 enrolled Revance Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.

Timeline

Start
2009-08
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic Topical

Indications